Ho Soo Chun

ORCID: 0000-0002-7066-6612
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Liver Disease Diagnosis and Treatment
  • Liver Disease and Transplantation
  • Hepatitis C virus research
  • Hepatitis B Virus Studies
  • Hepatocellular Carcinoma Treatment and Prognosis
  • Nutrition and Health in Aging
  • Alcohol Consumption and Health Effects
  • Cholangiocarcinoma and Gallbladder Cancer Studies
  • Metabolism, Diabetes, and Cancer
  • Nutritional Studies and Diet
  • Diet, Metabolism, and Disease
  • Cancer, Lipids, and Metabolism
  • Artificial Intelligence in Healthcare
  • Galectins and Cancer Biology
  • Pancreatitis Pathology and Treatment
  • Chemotherapy-induced cardiotoxicity and mitigation
  • Cardiovascular Disease and Adiposity
  • Diet and metabolism studies
  • Gastroesophageal reflux and treatments
  • Diagnosis and Treatment of Venous Diseases
  • Renal cell carcinoma treatment
  • Cancer Immunotherapy and Biomarkers
  • Helicobacter pylori-related gastroenterology studies
  • HIV-related health complications and treatments
  • Amoebic Infections and Treatments

Ewha Womans University
2021-2025

Ewha Womans University Medical Center
2021-2025

Yonsei University
2020-2023

Catholic University of Korea
2023

Severance Hospital
2020-2021

Sarcopenia is a significant indicator of the severity non-alcoholic fatty liver disease. We investigated whether sarcopenia could identify subgroups with different risk fibrosis and atherosclerotic cardiovascular disease (ASCVD) among subjects metabolic dysfunction-associated (MAFLD).Subjects from Korea National Health Nutrition Examination Survey 2008-2011 were selected (n = 8361). was defined using index. Hepatic steatosis as index ≥30. Significant fibrosis-4 (FIB-4) ≥2.67 or highest...

10.1002/jcsm.12754 article EN cc-by-nc Journal of Cachexia Sarcopenia and Muscle 2021-08-01

Abstract Background and Aims Cardiovascular disease (CVD) is the main cause of mortality in subjects with non‐alcoholic fatty liver (NAFLD). We investigated association between CVD risk metabolic dysfunction‐associated (MAFLD) or NAFLD influence significant fibrosis on risk. Methods Subjects who underwent a comprehensive medical check‐up were recruited (2014–2019). Significant was defined using score, fibrosis‐4 index, aspartate aminotransferase to platelet ratio FibroScan‐aspartate score....

10.1111/liv.15508 article EN Liver International 2022-12-31

Background/Aims: Metabolic dysfunction-associated fatty liver disease (MAFLD) is categorized into three subtypes: overweight/obese (OW), lean/normal weight with metabolic abnormalities, and diabetes mellitus (DM).We investigated whether fibrotic burden in differs across subtypes of MAFLD patients. Methods:This cross-sectional multicenter study was done cohorts subjects who underwent a comprehensive medical health checkup between January 2014 December 2020.A total 42,651 patients...

10.5009/gnl220400 article EN cc-by-nc Gut and Liver 2023-02-17

Clinical features of non-alcoholic fatty liver disease (NAFLD), but not fulfilling the diagnostic criteria metabolic dysfunction-associated (MAFLD), remain unclear. We investigated risk sarcopenia and cardiovascular (CVD) in MAFLD non-metabolic (MR) NAFLD. Subjects were selected from Korean National Health Nutrition Examination Surveys 2008-2011. Liver steatosis was assessed using index. Significant fibrosis defined fibrosis-4 index, categorized by age cut-offs. Sarcopenia as lowest quintile...

10.1111/jgh.16261 article EN Journal of Gastroenterology and Hepatology 2023-06-15

Cardiovascular disease (CVD) is the principal cause of death in patients with type 2 diabetes (T2D). In this study, we assessed whether liver fibrosis predicted risk CVD T2D.A total 1481 who had commenced oral antidiabetic drugs to treat newly diagnosed T2D between 2006 and 2010 were recruited. The fibrosis-4 index (FIB-4), non-alcoholic fatty score (NFS), BARD used assess fibrotic burden at time diagnosis.During follow-up period (median 88.1 [interquartile range 36.6-113.6] months), 242...

10.1111/jgh.15387 article EN Journal of Gastroenterology and Hepatology 2020-12-28

Transarterial radioembolization (TARE) has become widely used in the treatment of HCC, one most common causes cancer mortality worldwide. Here we investigated long-term clinical outcomes patients with hepatocellular carcinoma (HCC) treated TARE a multi-medical center Korea. A total 149 from 2008–2014 were recruited. The pre-treatment HCC stage was classified according to BCLC stage, which C and D defined as advanced HCC. Advanced Child–Turcotte–Pugh (CTP) score identified 62 (42%) 134 (90%)...

10.3390/cancers14020385 article EN Cancers 2022-01-13

Background and Aims: In the general population, previous studies reported that physical activity was associated with risk of hepatocellular carcinoma (HCC) development. However, it is unclear whether HCC development in patients chronic hepatitis B (CHB). We aimed to elucidate association between CHB patients. Methods: This nationwide cohort study involved treatment-naive (n = 9727) who started treatment entecavir or tenofovir answered self-reported questionnaires January 2012 December 2017,...

10.3390/cancers13143424 article EN Cancers 2021-07-08

Trans-arterial radioembolization (TARE) is a form of radiation therapy performed for hepatocellular carcinoma (HCC) via selective intra-arterial injection Yttrium-90-loaded microspheres. This was multi-center retrospective study consecutive patients with HCC who underwent TARE between July 2009 and May 2019. Using pre-treatment computed tomography imaging, the total cross-sectional area (cm2) abdominal skeletal muscle at third lumbar vertebra measured. The index (SMI) calculated by...

10.3390/cancers15215195 article EN Cancers 2023-10-28

Trans-arterial radioembolization (TARE) is a form of radiation therapy performed for hepatocellular carcinoma (HCC) via selective intra-arterial injection Yttrium-90 loaded microspheres. This was multicenter retrospective study consecutive patients with HCC who underwent TARE between July 2009 and May 2019. Using pre-treatment computed tomography imaging, the total cross-sectional area (cm2) abdominal skeletal muscle at third lumbar vertebra measured. The index (SMI) calculated by...

10.20944/preprints202309.1752.v1 preprint EN 2023-09-26

Backgrounds: It is unclear which patients benefit from resection in intermediate-stage-hepatocellular carcinoma (HCC). The authors aimed to identify high-risk for early recurrence among with resectable intermediate-stage HCC. Methods: This multicenter retrospective study included who underwent or trans-arterial chemoembolization (TACE) HCC (2008–2019). Multivariable Cox proportional analysis was performed when treated resection. A prediction score 2-year recurrence-free survival (RFS)...

10.1097/js9.0000000000000941 article EN cc-by-nc-nd International Journal of Surgery 2023-11-24

Abstract Aim Risk prediction models for hepatocellular carcinoma (HCC) development are available. However, the influence of antiviral therapy (AVT) on these in patients with chronic hepatitis B is unknown. Methods The dynamic changes risk during AVT and association between model B‐related HCC were investigated. Between 2005 2017, 4917 (3361 noncirrhotic, 1556 cirrhotic) recruited. Results mean age study population was 49.3 years 60.6% ( n = 2980) male. Chinese University‐HCC (CU‐HCC) score...

10.1111/hepr.13600 article EN Hepatology Research 2020-11-26

Background: The care cascade for hepatitis-C virus (HCV) faces a significant obstacle due to poor awareness, especially in patients undergoing elective surgery. To address this issue, we introduced an electronic medical record (EMR)-based automatic alert system 2021 enhance the awareness among surgical healthcare providers regarding HCV screening and referral rates.Methods: Implemented tertiary center South Korea, alerts surgeons order preoperative anti-HCV antibody tests, if needed, consult...

10.2139/ssrn.4724381 preprint EN 2024-01-01
Coming Soon ...